share_log

Piper Sandler Maintains Overweight on Achilles Therapeutics, Lowers Price Target to $8

Benzinga Real-time News ·  Dec 7, 2022 06:08

Piper Sandler analyst Joseph Catanzaro maintains Achilles Therapeutics (NASDAQ:ACHL) with a Overweight and lowers the price target from $10 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment